Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells

15 Jul 2021

Abstract excerpt

The transition from preclinical biological drug development into clinical trials requires an efficient upscaling process. In this context, bispecific antibody drugs are particularly challenging due to their propensity to form aggregates and generally produce low titers. Here, the upscaling process for a tetravalent bispecific antibody expressed by a piggyBac transposon-mediated stable HEK293 cell pool has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Protein purification and stability
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34273575
DOI: 10.1016/j.nbt.2021.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cellsPMID 34273575Read ↗

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO poolsSemantic proximity Read ↗

Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon systemSemantic proximity Read ↗

Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteinsSemantic proximity Read ↗

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read ↗

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read ↗

An innovative platform to improve asymmetric bispecific antibody assembly, purity, and expression level in stable pool and cell line developmentSemantic proximity Read ↗

Exploring Parametric and Mechanistic Differences between Expi293FTM and ExpiCHO-STM Cells for Transient Antibody Production OptimizationSemantic proximity Read ↗

Advances in recombinant antibody manufacturingSemantic proximity Read ↗

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read ↗

Screening and assessment of performance and molecule quality attributes of industrial cell lines across different fed‐batch systemsSemantic proximity Read ↗

Development of a 10 g/L process for a difficult-to-express multispecific antibody format using a holistic process development approachSemantic proximity Read ↗

Cell Line Techniques and Gene Editing Tools for Antibody Production: A ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.